TEL: +886-2-28712121*1296
E-mail: kunghao@gmail.com

1. Le PH, Kuo CJ, Hsieh YC, Chen TH, Lin CL, Yeh CT, Liang KH. Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation. BMC Cancer 19, 1190 (2019) doi:10.1186/s12885-019-6409-3
    
2. Liang, KH., Zhang, P., Lin, CL. Stewart C. Wang, Tsung-Hui Hu Chau-Ting Yeh, Grace L. Su, Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Dig Dis Sci (2019). https://doi.org/10.1007/s10620-019-05915-w
    
3. Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J. 2019 Oct 14. doi: 10.1038/s41397-019-0106-0.
    
4. Lai MW, Liang KH, Yeh CT. Diverse immune responses to HBV surface epitope variants after vaccine booster in adolescents immunized in infancy. Clin Microbiol Infect. 2019 Feb 13. pii: S1198-743X(19)30049-7. doi: 10.1016/j.cmi.2019.02.003.
    
5. Chu YD, Lai HY, Pai LM, Huang YH, Lin YH, Liang KH, Yeh CT. The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine. Cell Death Dis. 2019 Mar 11;10(3):240. doi: 10.1038/s41419-019-1486-4.
    
6. Liang KH, Ahn SH, Lee HW, Huang YH, Chien RN, Hu TH, Lin KH, Yeh CS, Hsu CW, Lin CL, Pan TL, Ke PY, Chang ML, Yeh CT A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study.Sci Rep. 2018 Jun 5;8(1):8608
    
7. Lai MW, Hsu CW, Lin CL, Chien RN, Lin WR, Chang CS, Liang KH, Yeh CT. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int. 2018 Sep;12(5):456-464.
    
8. Yeh CS, Hsu CW, Liang KH, Chen YC, Lin CL, Chien RN, Hu TH, Lin WR, Lai MW, Chu YD, Yeh CT. Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. J Gastroenterol Hepatol. 2018 Feb 8.33(8):1530-1537.
    
9. Lin WR, Hsu CW, Yeh CS, Chen YC, Chang ML, Liang KH, Lin CC, Chu YD, Yeh CT. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2018 Apr;14(2):e54-e63. doi: 10.1111/ajco.12745.
    
10. Le PH, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW, Yeh CT. Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. In Vivo. 2017 Jul-Aug;31(4):723-729.
     
11. Lin CL, Chien RN, Liang KH, Ke PY, Huang YH, Yeh CT. Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression. Anticancer Res. 2017 Jun;37(6):2885-2891.
     
12. Wang TH, Chen CC, Liang KH, Chen CY, Chuang WY, Ueng SH, Chu PH, Huang CG, Chen TC, Hsueh C. A Multivariate Evaluation of Factors Affecting the Quality of Freshly Frozen Tissue Specimens. Biopreserv Biobank. 2017 Aug;15(4):344-349. doi: 10.1089/bio.2016.0104. Epub 2017 May 25.
     
13. Wang TH, Wu CH, Yeh CT, Su SC, Hsia SM, Liang KH, Chen CC, Hsueh C, Chen CY. Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation. Oncotarget. 2017 Jul 18;8(47):82280-82293. doi: 10.18632/oncotarget.19316.
     
14. Liang KH, Yeh CT. O-glycosylation in liver cancer: Clinical associations and potential mechanisms. Liver Research. 2017 1(4):193-196.
     
15. Liang KH, Yeh TS, Wu RC, Yeh CN, Yeh CT. GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. Oncol Lett. 2017 Jun;13(6):4215-4223.
     
16. Tsou YK, Liang KH, Lin WR, Chang HK, Tseng CK, Yeh CT. GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget. 2017 Mar 16. doi: 10.18632/oncotarget.16253.
     
17. Huang YH, Liang KH, Chien RN, Hu TH, Lin KH, Hsu CW, Lin CL, Pan TL, Ke PY, Yeh CT. A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. Sci Rep. 2017 Mar 31;7(1):523. doi: 10.1038/s41598-017-00631-9.
     
18. Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors.BMC Infect Dis. 2017 Jan 5;17(1):9.
     
19. Yeh CT, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW. Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008-2012. Emerg Infect Dis. 2017 May;23(5):820-821.
     
20. Chen YT, Chen HW, Wu CF, Chu LJ, Chiang WF, Wu CC, Yu JS, Tsai CH, Liang KH, Chang YS, Wu M, Ou Yang WT. Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol Cell Proteomics. 2017 Feb 24. pii: mcp.M116.064758.
     
21. Liang KH, Lin CL, Hsu CW, Lai MW, Chien RN, Yeh CT. UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Sci Rep. 2016 Sep 26;6:34088. doi: 10.1038/srep34088.
     
22. Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogs for prevention of hepatocellular carcinoma in chronic hepatitis B. Journal of Infectious Diseases 2016 Mar 15;213(6):966-74.
     
23. Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Pharmacogenomics. 2016 Mar;17(4):353-66.
     
24. Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT  Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016 Dec 5;5(12):e273.
     
25. Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotidepolymorphisms. Sci Rep. 2016 Aug 1;6:30799.
     
26. Lai MW, Lin TY, Liang KH, Lin WR, Yeh CT. Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody.  Medicine (Baltimore). 2016 Dec;95(49):e5625.
     
27. Huang TS, Lin CL, Shyu YC, Yeh CT, Liang KH, Sun CC, Lu MJ, Chien RN. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: a population-based cohort study. J Gastroenterol Hepatol. 2016 Dec 8. doi: 10.1111/jgh.13670.
     
28. Fu JF, Liang ST, Huang YJ, Liang KH, Yen TH, Liang DC, Shih LY. Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. Int J Cancer. 2016 Nov 14. doi: 10.1002/ijc.30515.
     
29. Lin JW, Chang ML, Hsu CW, Chen YC, Liang KH, Huang YH, Lin CC, Yeh CT. Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. J Med Virol. 2016 Jun 8. doi: 10.1002/jmv.24595.
     
30. Wang TH, Yu CC, Lin YS, Chen TC, Yeh CT, Liang KH, Shieh TM, Chen CY, Hsueh C. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition. Oncotarget. 2016 May 26. doi: 10.18632/oncotarget.9635.
     
31. Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK, Yeh CT. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Medicine. 2016 Apr;95(17):e3487.